Eisai/Biogen’s Lecanemab: Pricing Pressure Builds Ahead Of Likely US Approval Of Alzheimer’s Drug

 
• By Cathy Kelly
  
Eisai Taking The Lead On Lecanemab • Source: Shutterstock

More from Market Access

More from Pink Sheet